SEP 4, 2026 · JOURNAL ARTICLE
Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
Science Advances
Preclinical study in animal models and ex vivo human cells demonstrating mechanism and tolerability of a novel IL-2 variant; supports rationale for clinical evaluation but lacks human efficacy data.
Study details
DesignPreclinical mechanistic and toxicology stud…
InterventionAlb–IL-2var RNA-LNP (engineered IL-2 varian…
ComparatorNot specified; no explicit control arm or c…